Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis
Top Cited Papers
Open Access
- 31 March 2016
- journal article
- Published by American Society of Hematology in Blood
- Vol. 127 (13), 1666-1675
- https://doi.org/10.1182/blood-2015-12-684399
Abstract
Key Points. Ruxolitinib treatment lessens immunopathology and prolongs survival in murine models of hemophagocytic lymphohistiocytosis.In vivo exposure to ruxoKeywords
This publication has 42 references indexed in Scilit:
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid LeukemiaNew England Journal of Medicine, 2013
- JAK Kinases in Health and Disease: An UpdateThe Open Rheumatology Journal, 2012
- Jakinibs: a new class of kinase inhibitors in cancer and autoimmune diseaseCurrent Opinion in Pharmacology, 2012
- Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative ColitisNew England Journal of Medicine, 2012
- Making Sense of the Cytokine Storm: A Conceptual Framework for Understanding, Diagnosing, and Treating Hemophagocytic SyndromesPediatric Clinics of North America, 2012
- Protection from Inflammatory Organ Damage in a Murine Model of Hemophagocytic Lymphohistiocytosis Using Treatment with IL-18 Binding ProteinFrontiers in Immunology, 2012
- Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocolBlood, 2011
- Perforin is a critical physiologic regulator of T-cell activationBlood, 2011
- Repeated TLR9 stimulation results in macrophage activation syndrome–like disease in miceJCI Insight, 2011
- Neutralization of IFNγ defeats haemophagocytosis in LCMV‐infected perforin‐ and Rab27a‐deficient miceEMBO Molecular Medicine, 2009